AI assistant
VOLITIONRX LTD — Director's Dealing 2022
Jun 24, 2022
34395_dirs_2022-06-24_810f9617-3bb6-4ada-9752-7b90d42d90f9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2022-06-23-05:00
Reporting Person: Michel Gaetan (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-06-23-05:00 | Common Stock | A | 25876 | — | Acquired | 40880 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-23-05:00 | Stock Option (Right to Buy) | $3.40 | A | 47684 | Acquired | 2031-10-04-05:00 | Common Stock (47684) | Direct |
Footnotes
F1: On October 4, 2021, the reporting person was awarded 39,809 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 25,876 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 12,939 units and 12,937 units on each of October 4, 2022 and October 4, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 13,933 restricted stock units subject to the award previously vested and remain subject to time-based vesting.
F2: On October 4, 2021, the reporting person was granted an option to purchase 73,360 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 47,684 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 23,842 shares on each of October 4, 2022 and October 4, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 25,676 shares subject to the award previously vested and remain subject to time-based vesting.